Stockscreener 앱 받기
6.88
8.52%
0.54
Silence Therapeutics Plc Adr 주식(SLN)의 최신 뉴스
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com
Silence Therapeutics' SWOT analysis: RNAi stock poised for growth amid clinical progress - Investing.com India
Silence Therapeutics announces additional results from SANRECO study - TipRanks
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - MSN
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Yahoo Finance
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks
SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks
Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Silence Therapeutics: Rising Assets Amid Growing Losses - TipRanks
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine - Investing.com
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease - Yahoo Finance
It makes sense and dollars to buy Silence Therapeutics Plc ADR (SLN) stock - SETE News
Silence Therapeutics Plc ADR (SLN) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
What Did We Find About Insider Trading At Silence Therapeutics Plc ADR (NASDAQ: SLN)? - Stocks Register
Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data - Investing.com UK
H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results By Investing.com - Investing.com South Africa
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years - Yahoo Finance
How did Silence Therapeutics Plc ADR (SLN) fare last session? - US Post News
Ratio Revelations: Silence Therapeutics Plc ADR (SLN)’s Financial Metrics in the Spotlight - The Dwinnex
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny - US Post News
Market Insight: Silence Therapeutics Plc ADR (SLN)’s Notable Drop, Closing at 16.70 - The Dwinnex
The 3 Best Gene Editing Stocks to Buy in August 2024 - Markets Insider
It would be worthwhile to take a closer look at Silence Therapeutics Plc ADR (SLN) - US Post News
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? - Yahoo Finance
Silence Therapeutics Plc ADR (SLN) deserves closer scrutiny – US Post News - US Post News
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com India
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics - Yahoo Lifestyle UK
Hardman & Co Insight: Survival of the UK life sciences sector - Research Tree
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Altria maintains stock target, Buy rating on FDA move By Investing.com - Investing.com UK
Zerlasiran shows promise in phase 2 study for cardiovascular risk By Investing.com - Investing.com
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates - Yahoo Finance
Kirby Corp CEO sells shares worth over $360k By Investing.com - Investing.com
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Yahoo Finance
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - MSN
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Silence Therapeutics Plc ADR (SLN-Q) QuotePress Release - The Globe and Mail
The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation - Yahoo Finance
Silence Therapeutics A Quieter Name In RNAi (NASDAQ:SLN) - Seeking Alpha
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
2.88%
2.65%
자본화:
|
볼륨(24시간):